WO2008007921A1 - Comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine et ayant des variations de dissolution réduites - Google Patents

Comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine et ayant des variations de dissolution réduites Download PDF

Info

Publication number
WO2008007921A1
WO2008007921A1 PCT/KR2007/003401 KR2007003401W WO2008007921A1 WO 2008007921 A1 WO2008007921 A1 WO 2008007921A1 KR 2007003401 W KR2007003401 W KR 2007003401W WO 2008007921 A1 WO2008007921 A1 WO 2008007921A1
Authority
WO
WIPO (PCT)
Prior art keywords
paroxetine hydrochloride
tablet
hydroxypropylmethylcellulose
containing sustained
release
Prior art date
Application number
PCT/KR2007/003401
Other languages
English (en)
Inventor
Hong-Ryeol Jeon
Do-Woo Kwon
Bong-Sang Lee
Su-Jun Park
Ji-Yun Moon
Hyun-Il Kim
Original Assignee
Ctc Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctc Bio, Inc. filed Critical Ctc Bio, Inc.
Publication of WO2008007921A1 publication Critical patent/WO2008007921A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a paroxetine hydrochloride-containing sustained-release tablet having reduced dissolution variation.
  • Paroxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI) and is used to treat depression and/or anxiety disorder.
  • Therapeutic agents of depression and/or anxiety disorder, such as SSRI usually have initial side effects like nausea, drowsiness, fatigue, etc. so that administration of such drugs often discontinue.
  • this kind of stop of administration is undesirable.
  • the sudden interruption of SSRI intake may make adverse effects such as dizziness, dysesthesia, somnipathy, agitation (anxiety), nausea, sweating and so on, so that a method of gradually decreasing the drug dose is preferred for the discontinuance of the drug.
  • sustained-release formulation or controlled-release formulation that can slowly release drug and have a long duration time is preferable for treating depression and/or anxiety disorder.
  • Paxil CRTM Panetine controlled-release tablet, Glaxo Smith Kline
  • Paxil CRTM is a bilayer tablet consisting of an active layer containing paroxetine hydrochloride and a support platform, and its manufacturing is difficult and complex, and needs a specific tabletting machine to make the bilayer tablet.
  • Paxil CRTM has a relatively big dissolution variation, which may cause a big absorption variation in a body. This in vivo variation is a very important factor when considering the necessity of maintaining blood level of paroxetine hydrochloride.
  • an object of the present invention is to provide a paroxetine hydrochloride-containing sustained-release tablet having desirable dissolution rate and reduced dissolution variation, wherein the method for manufacturing the tablet is simple and cost-effective, and does not need the specific machine for mass production.
  • the present invention provides a paroxetine hydrochloride-containing sustained-release tablet comprising paroxetine hydrochloride; first hydroxypropylmethylcellulose whose methoxyl content is 28-30% and hydroxypropoxyl content is 7-12%; second hydroxypropylmethylcellulose whose methoxyl content is 19-24% and hydroxypropoxyl content is 4-12%; and pharmaceutically acceptable excipient.
  • the present invention provides said paroxetine hydrochloride-containing sustained-release tablet wherein the viscosity of the first hydroxypropylmethylcellulose is between 3,000 and 5,600 cP when estimated as 2 wt% aqueous solution at 20 ° C, and the content of the first hydroxypropylmethylcellulose is 1-10 wt% based on the total weight of the tablet.
  • the present invention provides said paroxetine hydrochloride-containing sustained-release tablet wherein the viscosity of the second hydroxypropylmethylcellulose is between 80 and 120 cP when estimated as 2 wt% aqueous solution at 20°C, and the content of the second hydroxypropylmethylcellulose is 10-25 wt% based on the total weight of the tablet.
  • the present invention provides said paroxetine hydrochloride-containing sustained-release tablet wherein the viscosity of the second hydroxypropylmethylcellulose is between 3000 and 5600 cP when estimated as 2 wt% aqueous solution at 20 ° C, and the content of the second hydroxypropylmethylcellulose is 5-15 wt% based on the total weight of the tablet.
  • the present invention provides said paroxetine hydrochloride-containing sustained-release tablet wherein the pharmaceutically acceptable excipient is lactose.
  • the present invention also provides a paroxetine hydrochloride-containing sustained-release tablet comprising 7- 21 wt% of paroxetine hydrochloride; 1-10 wt% of first hydroxypropylmethylcellulose (whose methoxyl content is 28-30% and hydroxypropoxyl content is 7-12%); 5-25 wt% of second hydroxypropylmethylcellulose (whose methoxyl content is 19-24% and hydroxypropoxyl content is 4-12%); and 50-75 wt% of pharmaceutically acceptable excipient, based on the total weight of the tablet.
  • the present invention provides said paroxetine hydrochloride-containing sustained-release tablet wherein the tablet is coated by at least one release-controlling polymer, and more preferably, the release-controlling polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose acetate succinate, ethylcellulose, airanonio methacrylate copolymer, methacrylic acid copolymer, methacrylic acid-acrylic acid ethyl ester copolymer and polyvinylacetate/polyvinylpyrrolidone.
  • the release-controlling polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose acetate succinate, ethylcellulose, airanonio methacrylate copolymer, methacrylic acid copolymer, methacrylic acid-acrylic acid ethyl ester copolymer and polyvinylacetate/polyvinylpyrrolidone.
  • the present invention is based on the surprising fact that mixing hydroxypropylmethylcelluloses having different physical properties can epochally reduce dissolution variation of paroxetine hydrochloride, in addition to making the tablet have desirable dissolution pattern.
  • the present invention provides a paroxetine hydrochloride-containing sustained-release tablet comprising paroxetine hydrochloride; first hydroxypropylmethylcellulose whose methoxyl content is 28-30% and hydroxypropoxyl content is 7-12%; second hydroxypropylmethylcellulose whose methoxyl content is 19-24% and hydroxypropoxyl content is 4-12%; and pharmaceutically acceptable excipient.
  • first hydroxypropylmethylcellulose only is used to make the tablet, it is possible to make the tablet have desirable dissolution rate, but it is very difficult to control dissolution variation.
  • the dissolution variation can be reduced by increasing the amount of the first hydroxypropylmethylcellulose, but such increase of the amount of the first hydroxypropylmethylcellulose makes the dissolution rate too slow.
  • the dissolution variation is small, but the second hydroxypropylmethylcellulose makes the dissolution rate of paroxetine hydrochloride very slow.
  • a polymer having relatively low viscosity is used or the amount of the release-controlling polymer is decreased to step up the dissolution rate.
  • these methods make worse the mixing uniformity and increase the dissolution variation, which are thought to be caused by the very small amount of the polymer compared to the total weight of the tablet.
  • control of drug release is carried out with a viscous or water-insoluble polymer, and an amount of the polymer is adjusted to achieve a desirable drug release rate.
  • an identical formulation can not be necessarily applied to every kind of drug and drug release pattern may be changed according to drug's physical characteristics (such as drug solubility), drug content, excipients included in the formulation (such as binders, diluents and disintegrators) and the excipients' content, its manufacturing method, etc.
  • the desirable first hydroxypropylmethylcellulose is the hydroxypropylmethylcellulose whose viscosity is 3000-5600 cP when measured as 2 wt% aqueous solution at 20 ° C according to the method disclosed in U.S. Pharmacopeia (for example, Ubbelohde method), and whose content is 1-10 wt% based on the total weight of the tablet.
  • the desirable second hydroxypropylmethylcelluloses are the hydroxypropylmethylcellulose whose viscosity is 80-120 cP when measured as 2 wt% aqueous solution at 20 ° C according to the method disclosed in U.S.
  • Pharmacopeia for example, Ubbelohde method and whose content is 10-25 wt% based on the total weight of the tablet, and the hydroxypropylmethylcellulose whose viscosity is 3500-4500 cP and whose content is 5-15 wt%.
  • the pharmaceutically acceptable excipient of the present invention includes, but is not limited to, diluent, binder, lubricant, aid for dissolving, etc.
  • diluent include, but are not limited to, lactose, corn starch, microcrystalline cellulose and so on.
  • lubricant include, but are not limited to, magnesium stearate, stearic acid, sodium stearyl fumarate and so on. Lactose is preferable as diluent when considering the fact that lactose controls the dissolution rate of paroxetine hydrochloride after being mixed with hydroxypropylmethylcellulose .
  • the present invention provides the paroxetine hydrochloride-containing sustained-release tablet comprising 7-21 wt% of paroxetine hydrochloride; 1-10 wt% of first hydroxypropylmethylcellulose (whose methoxyl content is 28-30% and hydroxypropoxyl content is 7-12%); 5-25 wt% of second hydroxypropylmethylcellulose (whose methoxyl content is 19-24% and hydroxypropoxyl content is 4-12%); and 50-75 wt% of pharmaceutically acceptable excipient, based on the total weight of the tablet.
  • the drug release of the tablet is different according to the contents of the ingredients.
  • a sustained-release tablet a content-ratio change of all ingredients caused by a content change of one ingredient has a severe effect on dissolution pattern of the drug.
  • a desirable release pattern depends on a therapeutic method of depression and/or anxiety disorder.
  • the present invention also provides said paroxetine hydrochloride-containing sustained-release tablet wherein the tablet is coated with release-controlling polymer.
  • release-controlling polymer examples include, but are not limited to, hydroxypropylmethylcellulose acetate succinate, ethylcellulose, ammonio methacrylate copolymer (for example, Eudragit RLTM or Eudragit RSTM, Degussa, Germany), methacrylic acid copolymer (for example, Eudragit LTM or Eudragit STM, Degussa, Germany), and methacrylic acid-acrylic acid ethyl ester copolymer (for example, Eudragit L 100-55TM, Degussa, Germany) .
  • hydroxypropylmethylcellulose acetate succinate for example, ethylcellulose, ammonio methacrylate copolymer (for example, Eudragit RLTM or Eudragit RSTM, Degussa, Germany), methacrylic acid copolymer (for example, Eudragit LTM or Eudragit STM, Degussa, Germany), and methacrylic acid-acrylic acid
  • Figures 1 to 3 are graphs showing dissolution test results of conventionally available Paxil CRTM.
  • Figures 4 to 6 are graphs showing dissolution test results of comparative examples with HPMC 2208 only as polymer for controlling the drug release.
  • Figures 7 to 9 are graphs showing dissolution test results of comparative examples with HPMC 2910 only as polymer for controlling the drug release.
  • Figures 10 to 16 are graphs showing dissolution test results of the paroxetine hydrochloride-containing sustained- release tablets with HPMC 2208 and HPMC 2910 as polymer for controlling the drug release.
  • Dissolution test was performed according to the Paddle method of Korean Pharmacopeia at 50rpm for 5 hours. 12 of Paxil 12.5mg, 25mg and 37.5mg CRTM tablets, respectively, were used at a time, and their mean and standard deviation were shown in figures 1 to 3, respectively. The results were expressed as a percent (%) of dissolved paroxetine in medium compared to the total amount of paroxetine included in each tested tablet.
  • Paroxetine hydrochloride-containing sustained-release tablets containing only one kind of hydroxypropylmethylcellulose were prepared using ingredients and amounts shown in table 1.
  • Paroxetine hydrochloride, hydroxypropylmethylcellulose, lactose and hydroxypropylcellulose were mixed, and made into granules with ethanol, and then dried. After the dried granules were passed through a sieve, the passed granules and magnesium stearate were mixed and tabletted with a tabletting machine (TMI 1400, Kisan machinery, South Korea). Table 1
  • Dissolution pattern of the comparative examples 1-6 were evaluated like the method used in the dissolution test of the conventionally available tablet, and their mean and standard deviation were shown in figures 4 to 9, respectively.
  • Paroxetine hydrochloride-containing sustained-release tablets containing both the first hydroxypropylmethylcellulose whose methoxyl content is 28-30% and hydroxypropoxyl content is
  • Paroxetine hydrochloride, hydroxypropylmethylcellulose and lactose were mixed, and made into granules with ethanol, and then dried. After the dried granules were passed through a sieve, the passed granules, magnesium stearate and sodium lauryl sulfate were mixed and tabletted with a tabletting machine (TMI 1400, Kisan machinery, South Korea).
  • the paroxetine hydrochloride-containing sustained-release tablet was coated with a release-controlling polymer to lower the initial dissolution rate.
  • Hydroxypropylmethylcellulose acetate succinate Shin-Etsu, Japan
  • ethylcellulose and triethylcitrate were mixed as 9:1:1 of weight ratio, and the mixture was dissolved into the solvent mixture of 8:2 of ethanol and acetone to make about 6 wt% coating solution.
  • Dissolution pattern of the examples 1-7 were evaluated like the method used in the dissolution test of the conventionally available tablet, and their mean and standard deviation were shown in figures 10 to 16, respectively.
  • paroxetine hydrochloride- containing sustained-release tablet made with HPMC 2208 and HPMC 2910 showed greatly reduced dissolution variation as well as desirable dissolution rate, compared to the results of Paxil CR TM.
  • examples 1-7 are coated tablets and coating process usually increases dissolution variation, it is very surprising result that the dissolution variation of examples 1-7 are much smaller than those of comparative examples 1-6.
  • the present invention provides a paroxetine hydrochloride- containing sustained-release tablet that has reduced dissolution variation and whose manufacturing is simple and cost-effective.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine et ayant des variations de dissolution réduites. Grâce à ses variations de dissolution réduites, le comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine de l'invention permet de diminuer les différences entre individus et les différences internes à l'individu de l'absorption de l'hydrochlorure de paroxétine.
PCT/KR2007/003401 2006-07-14 2007-07-13 Comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine et ayant des variations de dissolution réduites WO2008007921A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060066456A KR20080007006A (ko) 2006-07-14 2006-07-14 용출편차가 감소한 염산파록세틴 서방정
KR10-2006-0066456 2006-07-14

Publications (1)

Publication Number Publication Date
WO2008007921A1 true WO2008007921A1 (fr) 2008-01-17

Family

ID=38923437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/003401 WO2008007921A1 (fr) 2006-07-14 2007-07-13 Comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine et ayant des variations de dissolution réduites

Country Status (2)

Country Link
KR (1) KR20080007006A (fr)
WO (1) WO2008007921A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
WO2004010998A1 (fr) * 2002-07-25 2004-02-05 Pharmacia Corporation Comprime a liberation prolongee comprenant de la reboxetine
WO2004058229A1 (fr) * 2002-12-24 2004-07-15 Biovail Laboratories Inc. Formulations d'inhibiteurs selectifs de recapture de la serotonine a liberation modifiee
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
WO2004010998A1 (fr) * 2002-07-25 2004-02-05 Pharmacia Corporation Comprime a liberation prolongee comprenant de la reboxetine
WO2004058229A1 (fr) * 2002-12-24 2004-07-15 Biovail Laboratories Inc. Formulations d'inhibiteurs selectifs de recapture de la serotonine a liberation modifiee
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제

Also Published As

Publication number Publication date
KR20080007006A (ko) 2008-01-17

Similar Documents

Publication Publication Date Title
TWI469781B (zh) 黏結劑於製造貯存安定性調合物上之用途
EP3265126B1 (fr) Formulation à base de combinaison de tésofensine et de métoprolol
CA2911486C (fr) Formulation a liberation modifiee
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
NO20121414A1 (no) Farmasoytiske sammensetninger omfattende hydromorfon og nalokson
WO2006112596A1 (fr) Preparation a liberation regulee contenant de l'hydrochlorure de tamsulosine
CN107753458B (zh) 尼莫地平片剂药物组合物和制法
WO2020061308A1 (fr) Compositions à libération prolongée comprenant du trihexyphénidyle
AU2004315136A1 (en) Extended release coated microtablets of venlafaxine hydrochloride
WO2017101858A1 (fr) Forme pharmaceutique de cyclobenzaprine à libération prolongée
WO2020144146A1 (fr) Tesofensine pour la réduction du poids corporel chez des patients prader-willi
EP2361616A1 (fr) Compositions à libération étendue pour ingrédients pharmaceutiques actifs à haute solubilité et haute perméabilité
WO2007011139A1 (fr) Comprime a liberation prolongee contenant de l'hydrochlorure de paroxetine et son procede de fabrication
WO2007129329A2 (fr) Préparation pharmaceutique à libération prolongée comprenant du chlorhydrate de venlafaxine
CN114432254A (zh) 一种硝苯地平控释片
WO2008007921A1 (fr) Comprimé à libération prolongée contenant de l'hydrochlorure de paroxétine et ayant des variations de dissolution réduites
TW201609196A (zh) 控制釋放製劑及其製備方法
US20140302138A1 (en) Extended release pharmaceutical compositions containing carbamazepine
TWI600425B (zh) 環苄普林之延釋劑型
WO2011132008A2 (fr) Composition pharmaceutique à libération contrôlée
KR20120052080A (ko) 에페리손 함유 서방정 및 이의 제조 방법
CA3029052A1 (fr) Tesofensine pour la reduction du poids corporel chez des patients atteints du syndrome de prader-labhart-willi
GB2569616A (en) Sustained release oral pharmaceutical compositions of dicycloverine
EP3474825A1 (fr) Formulation à libération prolongée comprenant de la tizanidine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07768732

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07768732

Country of ref document: EP

Kind code of ref document: A1